Peter J Goebell
Overview
Explore the profile of Peter J Goebell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
836
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitz-Drager B, Grossmann H, Goebell P, Kamat A, Black P
Urol Oncol
. 2025 Feb;
43(2):129-131.
PMID: 39986815
Objective: Professor Michael Droller is stepping down as Editor-in-chief of Urologic Oncology: Seminars and Original Investigations, a journal that he co-founded. This manuscript describes his relation with the International Bladder...
2.
Schmitz-Drager B, Bismarck E, Ebert T, Starlinger R, Dienes K, Ottillinger B, et al.
Urol Int
. 2025 Feb;
:1-17.
PMID: 39978320
Introduction: LEAN is a prospective, multicenter, noninterventional, German cohort study in patients with locally advanced and metastatic hormone-sensitive prostate cancer (PC). This analysis explores the efficacy and safety of leuprorelin...
3.
Frazer R, Arranz J, Estevez S, Parikh O, Krabbe L, Vasudev N, et al.
Curr Oncol Rep
. 2024 Nov;
26(12):1639-1650.
PMID: 39565522
Purpose Of Review: In this review, we discuss which patients with metastatic clear cell renal cell carcinoma (mRCC) may be most suitable for frontline tyrosine kinase inhibitor (TKI) monotherapy, a...
4.
Raval A, Chen S, Littleton N, Constantinovici N, Goebell P
BJU Int
. 2024 Nov;
135(3):408-421.
PMID: 39530232
Objective: To conduct a systematic literature review of real-world data (RWD) studies to summarise treatment patterns among men with metastatic hormone-sensitive prostate cancer (mHSPC). While androgen-deprivation therapy (ADT) is a...
5.
Goebell P, Cornelius F, Fernandez Milano A, Hessler S, Schulze M
Urologie
. 2024 Aug;
63(12):1251-1258.
PMID: 39207468
Background: The aim of this study was to determine the proportion of patients with prostate cancer (PCa) who remained on primary androgen deprivation therapy (ADT) after starting treatment for castration-resistant...
6.
Roghmann F, Goebell P, Dyrskjot L, van Rhijn B, Kafferlein H, Hakenberg O, et al.
Bladder Cancer
. 2024 Jul;
8(1):1-4.
PMID: 38994515
Marker research, and in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing...
7.
Schmitz-Drager C, Goebell P, Paxinos E, Bismarck E, Chen J, Balakrishnan P, et al.
Bladder Cancer
. 2024 Jul;
10(1):25-33.
PMID: 38993527
Background And Objective: Assessment of patients with hematuria (aH) remains a challenge in urological practice, balancing the benefits of diagnosing a potentially underlying bladder cancer (UCa) against the risks of...
8.
Benderska-Soder N, Ecke T, Kleinlein L, Roghmann F, Bismarck E, van Rhijn B, et al.
Urol Oncol
. 2024 Feb;
42(8):229-235.
PMID: 38403529
A plethora of urine markers for the management of patients with bladder cancer has been developed and studied in the past. However, the clinical impact of urine testing on patient...
9.
Goebell P, Raina R, Chen S, Rege S, Shah R, Grossman J, et al.
Future Oncol
. 2024 Feb;
20(14):903-918.
PMID: 38353055
To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians and evaluate treatment trends and baseline concordance versus guidelines internationally. Retrospective, cross-sectional data from the Ipsos Global...
10.
Uhlig A, Bergmann L, Bogemann M, Fischer T, Goebell P, Leitsmann M, et al.
Urol Int
. 2024 Feb;
108(3):198-210.
PMID: 38310863
Introduction: We evaluated the effectiveness and safety profile of the tyrosine kinase inhibitor sunitinib in patients with advanced or metastatic renal cell carcinoma (a/mRCC) in a real-world setting. Methods: We...